This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Xiangkun Yang, Ph.D.
Senior Scientist II at Prime Medicine
Speaker

Profile

Dr. Xiangkun (Shawn) Yang has 7 years of experience in the analytical and bioanalytical development area of biopharmaceutical industry. Dr. Yang obtained his Ph.D. from College of Pharmacy, University of Georgia in 2017. After that, Dr. Yang worked as an ORISE fellow at FDA, and at Regeneron Pharmaceuticals to develop novel analytical methods to characterize and quantitate antibody-based therapeutics and protein biomarkers. Dr. Yang joined Prime Medicine’s CMC organization (Technical Development & Operations, TDO) in 2021. Since then, Dr. Yang has been leading Prime’s guide RNA analytics team to support all aspects of analytical development including new method development, qualification, stability, tech transfer and regulatory submission for gene editing critical materials, drug substances and drug products.

Agenda Sessions

  • Analytical Development for Prime Editing Guide (peg)RNAs

    11:45am